Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
36.50
-0.78 (-2.09%)
Mar 7, 2025, 4:00 PM EST - Market closed
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Xenon Pharmaceuticals stock have an average target of 57, with a low estimate of 49 and a high estimate of 67. The average target predicts an increase of 56.16% from the current stock price of 36.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xenon Pharmaceuticals stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 5 | 5 | 5 | 5 | 3 |
Buy | 4 | 5 | 5 | 4 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 10 | 10 | 9 | 9 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +45.21% | Feb 24, 2025 |
Deutsche Bank | Deutsche Bank | Strong Buy Initiates $67 | Strong Buy | Initiates | $67 | +83.56% | Feb 11, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +45.21% | Dec 12, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +45.21% | Nov 13, 2024 |
Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +64.38% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
5.10M
Revenue Next Year
42.74M
from 5.10M
Increased by 738.04%
EPS This Year
-3.80
from -3.01
EPS Next Year
-4.22
from -3.80
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 78.8M | 113.5M | 322.1M | ||
Avg | 5.1M | 42.7M | 200.7M | ||
Low | n/a | n/a | 40.8M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | 2,126.1% | 653.7% | ||
Avg | - | 738.0% | 369.5% | ||
Low | - | - | -4.6% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -2.53 | -2.95 | -0.59 | ||
Avg | -3.80 | -4.22 | -2.63 | ||
Low | -4.23 | -4.90 | -4.76 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.